Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
115,567,681
-
Share change
-
-454,173
-
Total reported value
-
$27,687,316
-
Put/Call ratio
-
0%
-
Price per share
-
$0.24
-
Number of holders
-
62
-
Value change
-
-$90,786
-
Number of buys
-
20
-
Number of sells
-
29
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q2 2025
As of 30 Jun 2025,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,567,681 shares.
The largest 10 holders included
EcoR1 Capital, LLC, Long Focus Capital Management, LLC, Two Seas Capital LP, NEA Management Company, LLC, MPM ASSET MANAGEMENT LLC, MPM BIOIMPACT LLC, MORGAN STANLEY, Rock Springs Capital Management LP, ACADIAN ASSET MANAGEMENT LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
62
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.